Hematopoietic progenitor cell transplantation in multiple myeloma

The median survival of conventionally treated patients with multiple myeloma is 3 years. Modifications of conventional chemotherapy and the administration of interferon-α have failed to show an improved survival in most randomized trials. Therapy with dose-escalated alkylating agents (i. e. melphala...

Full description

Saved in:
Bibliographic Details
Main Authors: Goldschmidt, Hartmut (Author) , Hegenbart, Ute (Author) , Haas, Rainer (Author) , Hunstein, Werner (Author)
Format: Article (Journal)
Language:English
Published: 1995
In: Onkologie
Year: 1995, Volume: 18, Issue: 6, Pages: 518-523
ISSN:1423-0240
DOI:10.1159/000218652
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000218652
Get full text
Author Notes:H. Goldschmidt, U. Hegenbart, R. Haas, W. Hunstein
Description
Summary:The median survival of conventionally treated patients with multiple myeloma is 3 years. Modifications of conventional chemotherapy and the administration of interferon-α have failed to show an improved survival in most randomized trials. Therapy with dose-escalated alkylating agents (i. e. melphalan 140 mg/m2) induced higher remission rates than conventional treatment. If followed by allogeneic or autologous hematopoietic progenitor cell transplantation, the hematotoxicity of the described dose-escalated treatment could be reduced. Results of transplantation trials are summarized and discussed. The transplantation of autologous peripheral blood progenitor cells results in a faster hematopoietic reconstitution and a decreased high-dose therapy-related morbidity compared to autologous bone marrow and should therefore be preferred. Although the randomized French myeloma trial showed a significant survival advantage for patients following autologous transplantation, further randomized prospective studies are required to evaluate the role of blood progenitor cell transplantation after high-dose treatment in multiple myeloma. Prognostical factors and future treatment modalities for myeloma are discussed.
Item Description:Elektronische Reproduktion der Druck-Ausgabe 11. Mai 2009
Gesehen am 15.05.2025
Physical Description:Online Resource
ISSN:1423-0240
DOI:10.1159/000218652